ASB17

Across TCGA pan-cancer cohorts, ASB17 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASB17 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ASB17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ASB17 expression acts as an unfavorable survival marker, although some lineages such as LUSC and SKCM show a favorable association.

BLCA, LUSC, and GBM are the cancer types where ASB17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.200	0.616	.013	15	view →
LUSC	DFS	Median	All	0.867	0.371	.028	4	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →
COAD	DFS	Median	All	0.136	0.561	.019	3	view →
SKCM	DFS	Median	II,III,IV	0.789	0.216	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ASB17–BLCA (DFS)

Open the BLCA breakdown →